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Abstract
A Japanese family with atypical type I familial amyloidotic
polyneuropathy (FAP) in Iiyama, Japan was studied. Most of
the family members have dysfunctions of the central nervous
system, in addition to typical symptoms of type I FAP. The
transthyretin (TTR, also called prealbumin) gene of the atypi-
cal FAP(FAP-IY) was analyzed with recombinant DNA tech-
niques and a RIA method. FAP-IY was found to have the
mutation responsible for the methionine-for-valine substitution
at position 30 of TTR, as in the case of typical type I FAP.
However, analysis of DNA polymorphisms in the TTR locus
showed that FAP-TY has a genetic background differing from
that of the typical type I FAP. These observations lead to the
consideration that a genetic factor(s) involved in the dysfunc-
tion of the central nervous system may locate in a chromosome
region in close proximity to the TTR gene.
Introduction
Familial amyloidotic polyneuropathy (FAP)' is a dominantly
inherited disorder characterized by systemic deposition of
amyloid fibrils, and is clinically classified into four types (1).
Type I FAP is the most common type and is manifested by
sensory dissociation and autonomic involvement followed by
motor neuropathy. Amyloid fibrils of type I FAP of Portu-
guese (2, 3), Japanese (4, 5), and Swedish (6, 7) origins contain
a variant of transthyretin (TTR, also called prealbumin) with
an amino acid substitution at position 30 (methionine-for-va-
line, 30vml _ Met) as a major component. Analysis ofnormal and
patient types ofTTR gene revealed that the 30v, _. Met substi-
tution is caused by a single base change G -- A and that this is
the only base change specific for type I FAP in the TTR gene
(8-10). These findings led to the establishment of diagnostic
methods for FAP using RIA (1 1), immunoblotting procedure
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1. Abbreviations used in this paper: FAP, familial amyloidotic polyneu-
ropathy; SCD, spinocerebellar degeneration; TTR, transthyretin;
30vma Met, methionine-for-valine substitution at position 30.
(12), and recombinant DNA techniques (8, 13). It became
clear that type I FAP is a molecular disorder of TTR.
The disease process of type I FAP is not well understood at
the molecular level. One approach to this issue may be a care-
ful analysis of atypical FAP compared with the typical form.
Such a study should provide a clue to genetic or other factors
involved in the disease process. FAP families with variant TTR
having amino acid substitutions other than the 30va1 -. Met
change have been reported (14-17). An atypical FAP family
has been detected in Iiyama, Japan (18, 19). In the course of
the disease, patients with atypical FAP(FAP-IY) often show
cerebellar signs of dysarthria, incoordination in the limbs,
ataxic gait, and pyramidal tract signs, in addition to typical
clinical features of type I FAP. The symptoms of central ner-
vous system (CNS) involvement and type I FAP appear to be
linked each other (18, 19). These observations raise the possi-
bility that FAP-IY is a new phenotype of FAP (18).
We analyzed FAP-IY with recombinant DNA and RIA
techniques and found that patients ofFAP-IY carry the muta-
tion responsible for the 30vw _. Met substitution in the TTR
gene, just as in the case of typical type I FAP. However, the
family has a different genetic background from that of typical
FAP families ofJapan. The results are discussed in terms ofthe
factor(s) that may be involved in dysfunction of the CNS in
case of FAP-IY.
Methods
Subjects. Data on a family with FAP-IY have been reported (18, 19).
The pedigree of this family and the clinical features are given in Fig. 1.
Information was obtained for the 30 members, and 18 were available
for clinical examination. Details of the neurological signs are summa-
rized in Fig. 1. Peripheral neuropathy was present in 1 1, and there were
11 with signs ofCNS involvement, such as cerebellar signs (dysarthria,
impaired finger-to-nose testing, dysdiadochokinesia, and ataxic gait)
and hyperreflexia. Babinski's sign was present in five (11-6, 11-9, III-1,
III-10, III-1 1).
Preparation of high-molecular weight DNA and blotting experi-
ments. Peripheral blood samples (10-20 ml) were obtained from avail-
able members of the FAP-IY family (IV-1, IV-2, IV-3, 111-10, 111-11,
V- 1), and high-molecular weight DNA was prepared from white blood
cells by the procedure of Ryan et al. (20) with minor modifications.
Southern blotting was carried out as described by Maniatis et al. (21).
Unless noted, the cDNA clone pHH64-1 was used as the probe. A
polymorphic base change that does not result in restriction site
polymorphism was identified using a pair of oligonucleotide
probes (5' TGCTATAGTAACTCCCTCT 3' and 5' TGCTATAGT-
CACTCCCTCT 3') after the specific DNA region had been enzymatic-
ally amplified using a set of primers (5' GGGTCTGGATG-
TAGTTCTGA 3' and 5' GTAATGTACCATACATAGGG 3'), ac-
cording Saiki et al. (22).
Construction and screening ofa genomic DNA library. High-mo-
lecular weight DNA of a FAP-IY patient (III-10) was completely di-
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gested with Eco RI and DNA fragments of 4-6 and 8-10 kb long were
isolated by 5-20% sucrose gradient centrifugation. Exons were found
on 9 kb and 4.89 kb Eco RI fragments (Fig. 2 A). These fragments were
ligated to X gtWES arm DNA and packaged into phage particles by the
in vitro packaging reaction (21). Phages were grown on L-agar plates,
with Escherichia coli K12 (LE392) as the host. - 6.0 X 10 indepen-
dent clones were obtained. The DNA library was screened by the
plaque hybridization technique (23) using 32P-labeled DNA fragments
from human cDNA (pHH64-1) (8) as the probe, and five clones carry-
ing Eco RI 9-kb fragment and three clones of 4.89-kb fragment were
obtained.
Nucleotide sequence analysis. Recombinant phage DNA was di-
gested with restriction endonuclease, and DNA fragments to be se-
quenced were subcloned into the plasmid pUC 9. The nucleotide se-
quence was determined by the dideoxy chain termination method
described by Hattori and Sakaki (24).
RIA ofvariant TTR. Variant TTR with the 30val _ Met substitution
in serum was measured by the RIA based on FAP-specific nonapeptide
(position 22-30) of the TTR variant ( 1). 5 Ail of serum were treated
with cyanogen bromide followed by trypsin before RIA, as described
by Nakazato et al. (1 1).
Results
Southern blotting analysis. Several different types of amino
acid substitution of variant TTR have been noted in FAP:
30va _. Met (2-7), isoleucine for phenylalanine at position 33
(33Phe - lie) (15), glycine for threonine at position 49
(49Thr - Gly) (17), alanine for threonine at 60 (60Thr Ala) (16),
and serine for isoleucine at 84 (8411e _ ser.) (14). Mutations re-
sponsible for these amino acid substitutions (except
49Thr -- Gly) can be detected by Southern blotting, using appro-
priate restriction enzymes: 30Val
--
Met by Nsi I, Bal 1 (8, 13) and
33Phe_ lle by Bcl 12 using pHH64- 1 as a probe, and 60Thr -- Ala by
Pvu 11 (16) and 8411,e _ ser by Alu 12 using the 0.88-kb Alu I
fragment (from position 3,844 to 4,728 [10]) as a probe. DNA
from FAP-IY patients were digested with these restriction en-
zymes and subjected to Southern blotting analysis. As shown
2. These have not been experimentally demonstrated, rather were pre-
dicted from the cDNA sequence.
Figure 1. Pedigree and clinical features (18, 19) of
FAP-IY showing affected members of the FAP-IY
family. DNA samples were available from 111-10
(48 yr old), III-1 1 (45 yr old), IV-1 (32 yr old),
IV-2, IV-3 (18 yr old) and V-1 (4 yr old).
in Fig. 2 B, DNAs of III- 10, 1 1, IV- 1, and V-I digested with Nsi
I showed two additional bands of 4.90 and 1.45 kb, indicating
that patients with FAP-IY carry the mutation responsible for
30va -_ Met, heterozygously, just as in the case of type I FAP (8,
13). No significant difference was observed in the blotting
profiles of FAP-IY DNAs digested with Bcl I, Pvu II, and Alu I
(data not shown). The absence ofthe 49Thr - Gly substitution in
FAP-IY became evident by the sequence analysis described
below.
Nucleotide sequence analysis of FAP-IY type TTR gene.
We then asked whether the FAP-IY TTR gene has additional
mutations in exons and possible regulatory regions. The
human TTR gene consists of four exons, and some possible
regulatory signals have been identified in the 5' flanking region
and introns (10). The structure of the TTR gene is schemati-
cally shown in Fig. 3. Clones carrying the 9.0-kb and 4.89-kb
Eco RI fragments that cover most of the TTR gene (10) were
isolated from a genomic DNA library of a FAP-IY patient
(III-10), as described in Methods. As the patient is heterozy-
gous for the mutation, the Eco RI fragments can be derived
from both normal and mutant chromosomal genes. Two types
of the 4.89-kb Eco RI fragments were cloned, based on the
polymorphisms of Fnu 4H1I site at position 5,610 (for position
numbers, see references 9 and 10). Two types of the 9.0-kb
fragment (with and without Nsi I site at exon 2) were also
cloned. The nucleotide sequences ofthese four fragments (two
9.0 kb and two 4.89 kb) were determined. Sequenced regions
are indicated at the bottom of Fig. 3. The results show that
except for the mutation responsible for the 30va, _ Me, change
in exon 2, no base change was present in the coding and possi-
ble regulatory regions of FAP-IY TTR gene in comparison
with the normal TTR gene (10) cloned from Maniatis' human
genomic DNA library (25).
RIA ofvariant TTR in serum. Variant TTR with 30va _- Met
in serum can be quantitatively measured by RIA after treat-
ment with cyanogen bromide followed by tryptic digestion
(1 1). Using this method, we asked whether the FAP-IY shows
differences in serum levels of the variant TTR, in comparison





























Figure 2. Southern blotting analysis of FAP-TY. (A) Sche-
matic presentation of restriction sites for Eco RI and Nsi I
in TTR gene. Horizontal bars at the middle show regions
cloned from the genomic DNA library. Positions of frag-
ments found in (B) are presented by horizontal bars at the
bottom. Stippled boxes show positions of probe DNA
(pHH64-1). N, Nsi I site; E, Eco RI site; N*, Nsi I site gener-
ated in the mutated TTR gene; +, presence of cleavage at N*
site; -, absence of cleavage. (B) DNA from patients of FAP-
IY (III-10, III-1 1, IV-1) and clinically normal familial
members (IV-2, V- 1, IV-3) were digested with Nsi I and sub-
jected to Southern blotting analysis, using pHH64-1 as a
probe. Sizes of fragments are indicated in kb. Serum levels
of the variant TTR are displayed under each lane. Because
the amount ofDNA of III- 10 was limited, the signals were
weak but the bands at 4.90 kb and 1.45 kb were clear.
with typical type I FAP. As indicated at the bottom of Fig. 2 B,
three FAP-IY patients showed values of 8.10 mg/dl (IV-1),












Figure 3. Structure, restriction map (Eco RI, Pst I), and sequencing
strategy of the FAP-IY TTR gene. The overall structure of the gene
shown at the top was drawn based on the results of Sasaki et al. (10).
Filled boxes are exons. Alu family sequence (Alu) and open reading
frames (ORF) are shown by horizontal solid and open arrows, re-
spectively. Positions of possible glucocorticoid response elements
(GRE), possible enhancer, TATA box, and CAAT box are also indi-
cated. Position of 30val_- Met substitution is indicated at the very top.
Arrows at bottom show sequencing strategy. Short vertical bars at
arrow origins indicate restriction sites at which sequencing was
started. Open circles indicate sites for specific sequencing primers.
the serum levels of the variant TTR. These levels are close to
the value in typical type I FAP patients (9.18±2.69 mg/dl)
(26). A family member carrying the mutation (V-I) also
showed a similar level ofthe variant TTR long before the onset
of the disease (Fig. 2 B) as in the case of typical type I FAP.
These findings indicate that there is no significant difference in
expression of the variant TTR gene between typical FAP and
FAP-IY.
Haplotype analysis ofFAP. Our findings suggested that in
FAP-IY, there is a certain factor(s) other than the TTR gene
that is responsible for the clinical feature characteristic of
FAP-IY, that is, dysfunction of the CNS. To determine the
genetic background of the FAP-IY family, we analyzed two
polymorphic markers in the TTR gene (9, 27). Our previous
work showed that there are six polymorphic base changes in
the TTR gene region (9). Among them, the association ofT or
G change at nucleotide position 1,218 and G orA (Msp I site +
or -) change at position 2,537 to the G or A change at position
1,679 responsible for the 30vw substitution in exon 2 was
examined. At first, DNA was digested with both Bal I and Msp
I, which makes the four types of haplotypes distinguishable by
length of the restriction fragments (Fig. 4 A). The blotting
profiles ofFAP-IY families are shown in Fig. 4 B together with
those of normal and typical type I FAP subjects. The mutation
responsible for the 30vw -. Met substitution (Bal I site (+), geno-
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Figure 4. Detection of polymorphic changes in the TTR gene. (A)
Schematic presentation of polymorphic sites for Msp I (M*) and Bal
I (B*) in the TTR gene region. The regions covered by the probes
(pHPrA 10) are indicated by the stippled box. Expected sizes of re-
striction fragments for each haplotype are indicated by horizontal
type B) was found to be associated with the Msp I site (+)
(genotype M) in patients of FAP-IY. On the contrary, all 28
patients with typical type I FAP showed the Bal I site (+)
(genotype B) with Msp I (-) (genotype m) (details will be
published elsewhere).
The nucleotide at position 1,218 (G or T) was determined
either by nucleotide sequencing or by dot blot hybridization
using a pair of 19 mer nucleotide probes, as described in
Methods. The results showed that the genotype ofBal I site (+)
(genotype B) is associated with a G residue at position 1,218 in
all five typical type I FAP patients examined, but FAP-1Y
patients (III-10, 11, IV-1) had a T residue at 1,218 associated
with Bal I (+). These results are summarized in Table I. It is
evident that FAP-TY and typical type I FAP families in Japan
have different haplotypes, the former being 'TBM' and the
latter being 'GBm'. These findings strongly suggest that the
lines. (B) Southern blotting analysis of polymorphic changes in nor-
mal control (lane 1), typical type I FAP (lane 2), and FAP-IY family
(lanes 3-8). DNAs were digested with both Bal I and Msp I for all
subjects. Haplotypes of each subject are shown at bottom. Size of
fragments are indicated in bp.
family with FAP-TY has a genetic background differing from
that of the typical type I FAP families in Japan.
Discussion
Although the most common type of hereditary generalized
amyloidosis in Japan is type I FAP (28, 29), a family of atypi-
cal type I FAP (FAP-IY) with CNS involvement has been
found in Iiyama. The most remarkable feature of FAP-IY is
the disorder of the CNS: cerebellar signs of dysarthria, incoor-
dination in limbs, ataxic gait, and pyramidal tract signs. Al-
though the patient IV- has at present a peripheral neuropathy
(Fig. 1), the symptom ofCNS involvement may appear in the
future. For example, the Babinski's sign has recently become
evident in patients III-10 and III-I 1 (unpublished data).
Table I. Nucleotide Substitutions in TTR Genes
Positions
In reference 10 1,218 1,679 2,422 2,537 5,198 5,610 5,708
(In reference 33) (637) (1,098) (1,841) (1,956) (4,618) (5,030) (5,128) Reference
Normal T G G G A C G 10
(Bal l-) (Msp 1+) (Fnu 4HI-)
Typical type I FAP G A C A C G T 9
(Bal 1+) (Msp I-) (Fnu 4HI+)
FAP-IY T A G This work
(Bal 1+) (Msp I+)
Normal G* G G G A C G 33
(Bal I-) (Msp 1+) (Fnu 4HI-)
The nucleotide sequence ofTTR gene has been published by our group (10) and by others (33). The numbering system for base positions by
reference 10 is employed in this work. Although the sequence in reference 10 was revised after its publication (filed in GenBank DNA data
base), the original numbering system has been employed to avoid confusion. Even after reversion, there are several differences (including dele-
tions and insertions) between the data. The two numbering systems cannot be simply converted. * It is not clear whether the sequenced frag-
ment is from the Maniatis's library or a Japanese genomic library.







We analyzed the structure and expression of FAP-IY TTR
gene using recombinant DNA techniques and an RIA method
and found that the FAP-IY patients carry the mutation re-
sponsible for the 30va -- Met substitution as in the case oftypical
type I FAP. No significant difference was observed in quality
and quantity ofthe variant TTR in serum between typical type
I FAP and FAP-IY. These findings suggested that a certain
factor(s) other than the TTR gene is involved in the dysfunc-
tion of the CNS characteristic for FAP-IY. As shown in Fig. 1,
seven of 11 patients with peripheral neuropathy had obvious
signs of CNS involvement, that is, the cerebellar signs and/or
Babinski's sign (11-6, 9, III- 1, 3, 8, 10, 1 1). The remaining three
(111-6, 9, 12) had a hyperreflexia. Thus, symptoms of type I
FAP appear to be closely associated with dysfunction of the
CNS in this family. The association of peripheral neuropathy
with CNS involvement has not been detected in other FAP
families in Japan. These findings suggested that such a fac-
tor(s) is genetically determined.
It is conceivable that FAP-IY is a combination of type I
FAP and some hereditary disorders ofthe CNS. FAP-IY shares
clinical features (cerebellar ataxia and pyramidal tract signs)
with familial cerebellar ataxia and cerebrovascular amyloid
(30), and also with hereditary spinocerebellar degeneration
(SCD). Ikeda et al. (18) pointed out that the computerized
tomography scan imaging of FAP-IY patients shared findings
similar to those with SCD, although no patient with FAP-IY
has been autopsied. FAP patients in Japan number - 1,000-
2,000 and the prevalence of SCD (containing hereditary type
and sporadic type) is roughly 1-7/100,000; Thus, the probabil-
ity of a combination of these two diseases in one family would
be extremely low, but not zero. Alternatively, the variant TTR
with the 30val -_ Met substitution may directly cause dysfunction
of the CNS in the presence of different genetic backgrounds.
Further clinical and pathological studies will be required to
determine the molecular basis of the dysfunction of the CNS.
The genetic factor(s) involved in the dysfunction of CNS, if
present, is probably linked to the TTR gene, which is assigned
to ql 1.2-12.1 of chromosome 18 (31, 32).
In conclusion, we obtained evidence that FAP-IY has the
same mutation as type I FAP in the TTR gene. A genetic
factor(s) involved in the dysfunction of the CNS may locate in
a chromosomal region in close proximity to the TTR gene.
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